Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
NCT02228382 · Pfizer · PHASE4 · terminated · last registry update 2021-12-30 · Chronic myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in chronic myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-13Phase 3 first posted: Novartis Pharmaceuticals, Asciminib + Nilotinib (NCT05456191)
- 2022-06-10Phase 3 first posted: Sarit Assouline, Asciminib + Imatinib (NCT05413915)
- 2022-02-15Results posted on the registry: Novartis Pharmaceuticals, Asciminib + Bosutinib (NCT03106779)
- 2021-07-21Phase 3 first posted: Novartis Pharmaceuticals, Imatinib + Nilotinib (NCT04971226)
- 2021-07-01Phase 3 first posted: Novartis Pharmaceuticals, ABL001 40mg BID + ABL001 80mg QD (NCT04948333)
- 2021-01-14Results posted on the registry: Novartis Pharmaceuticals, Nilotinib followed by treatment-free (NCT01784068)
- 2021-01-13Results posted on the registry: Novartis Pharmaceuticals, nilotinib (NCT01698905)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision